文献速递角膜与眼表疾病眼整形与眼眶

实体器官移植受者眼表肿瘤风险增加

Increased Risk for Ocular Surface Neoplasia in Recipients of Solid Organ Transplant.
PubMed 文献 · Am J Ophthalmol · 2026-06-28

本研究基于TriNetX美国协作网络的回顾性队列,纳入使用他克莫司等免疫抑制剂的成人,经倾向评分匹配后分析显示免疫抑制治疗者发生眼表肿瘤的风险为对照组的2.30倍(OR 2.30,95%CI 1.36–3.89),建议对该人群进行适当眼科监测。

要点

  • 免疫抑制治疗者眼表肿瘤风险显著升高(OR 2.30,95%CI 1.36–3.89)。
  • 需额外用药暴露的敏感性分析结果一致(OR 3.67,95%CI 1.94–6.95)。
  • 排除所有实体器官移植受者后关联不显著(OR 1.31,95%CI 0.64–2.69)。

核心结论

  • 接受免疫抑制治疗的实体器官移植受者发生眼表肿瘤的风险显著增加。
  • 建议对该人群进行适当的眼科监测以筛查眼表肿瘤。

研究设计与样本

  • 回顾性队列研究,使用TriNetX美国协作网络数据。
  • 纳入≥18岁使用口服或静脉他克莫司、环孢素、西罗莫司、霉酚酸酯或钠、依维莫司或硫唑嘌呤的个体。
  • 排除无后续眼科随访或既往有眼表肿瘤诊断者;对照组为多次眼科随访、无既往眼表肿瘤诊断且未暴露于目标药物者。
  • 采用倾向评分匹配(1:1)控制人口学和已知眼表肿瘤风险因素等协变量。

主要发现

  • 匹配后共纳入43 580人,暴露队列新发眼表肿瘤46例(0.11%),对照队列20例(0.05%)。
  • 免疫抑制治疗者研究期间发生眼表肿瘤的风险为对照组的2.30倍(OR 2.30,95%CI 1.36–3.89)。
  • 要求额外用药暴露的敏感性分析显示OR 3.67(95%CI 1.94–6.95)。
  • 控制其他免疫抑制治疗适应症的敏感性分析显示OR 1.70(95%CI 1.06–2.74)。
  • 排除所有实体器官移植受者后关联不显著(OR 1.31,95%CI 0.64–2.69)。

关键数值与推荐

  • 暴露组新发眼表肿瘤46例(0.11%),对照组20例(0.05%)。
  • 主要分析OR 2.30(95%CI 1.36–3.89)。
  • 额外用药暴露敏感性分析OR 3.67(95%CI 1.94–6.95)。
  • 控制其他适应症敏感性分析OR 1.70(95%CI 1.06–2.74)。
  • 排除实体器官移植受者后OR 1.31(95%CI 0.64–2.69)。

临床怎么用

  • 对接受免疫抑制治疗的实体器官移植受者应提高眼表肿瘤筛查意识。
  • 建议在该人群中开展适当的眼科监测以及时发现眼表肿瘤。

局限性

  • 排除所有实体器官移植受者后关联不显著,提示风险可能主要集中于移植受者亚群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recipients of solid organ transplants (SOT) undergo long-term immunosuppressive therapy, placing them at a high risk for developing skin cancer. Given that the conjunctiva and skin share key risk factors for neoplasia, we conducted a study to examine the association between immunosuppressive agents used in recipients of SOT and risk of ocular surface neoplasia (OSSN). DESIGN: Retrospective cohort study using the TriNetX US Collaborative Network. PARTICIPANTS AND CONTROLS: We included individuals ≥18 years of age receiving oral or intravenous tacrolimus, cyclosporine, sirolimus, mycophenolate mofetil or sodium, everolimus, or azathioprine. Individuals without subsequent ophthalmology follow-up or with prior OSSN diagnoses were excluded. The control cohort included individuals with multiple ophthalmology follow-ups, no prior OSSN diagnoses, and no exposure to the medications of interest. METHODS: Propensity score matching (1:1) was used to control for covariates such as demographics and known risk factors of OSSN. Odds ratios with 95% confidence intervals were calculated using univariate analysis to compare outcomes. Multiple sub analyses were performed, in which we required additional exposure to the medications, controlled for common autoimmune disorders, or excluded all recipients of SOT. MAIN OUTCOME MEASURES: Risk of a new OSSN diagnosis during the study period. RESULTS: After matching, 43 580 individuals were included for analysis. There were 46 (0.11%) new cases of OSSN in the exposure cohort and 20 (0.05%) cases in the control cohort. Those on immunosuppressive therapy had a 2.3 times higher risk of developing OSSN (odds ratio [OR] 2.30 [95% CI 1.36 to 3.89]) during the study period. Sensitivity analyses requiring additional instances of medication exposure (OR 3.67 [95% CI 1.94 to 6.95]) or controlling for other indications of immunosuppressive therapy (OR 1.70 [95% CI 1.06 to 2.74]) showed consistent results. Excluding all recipients of SOT resulted in no significant association with OSSN (OR 1.31 [95% CI 0.64 to 2.69]). CONCLUSIONS: Recipients of SOT who underwent immunosuppressive therapy experienced a significantly increased risk of developing OSSN. Appropriate ophthalmological monitoring for OSSN in these populations is recommended.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Lin F, Margo CE, Espana EM, et al. Increased Risk for Ocular Surface Neoplasia in Recipients of Solid Organ Transplant. Am J Ophthalmol. 2026. PMID: 42365872. doi:10.1016/j.ajo.2026.06.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。